Abstract
Nicotinic acid is the oldest hypolipidemic agent in use, since 1955. It possesses broad-spectrum lipidmodifying properties including reduction of total cholesterol, low density lipoprotein (LDL) cholesterol and triglycerides. In addition, nicotinic acid is the most potent available hypolipidemic agent for increasing plasma high density lipoprotein (HDL) cholesterol and decreasing lipoprotein (a) levels. Clinical trials have demonstrated that nicotinic acid can decrease cardiovascular morbidity and mortality. However, nicotinic acid is underused in the clinical setting due to its high rate of side effects, including flushing, gastrointestinal disorders, rash, hyperglycemia and hyperuricemia. The nicotinic acid-associated side effects and their management are the focus of this review.
Keywords: Adverse events, niacin, nicotinic acid, side effects, toxicity, laropiprant, high density lipoprotein, gastrointestinal disorders, flushing, rash
Current Vascular Pharmacology
Title: What Restricts the Clinical Use of Nicotinic Acid?
Volume: 9 Issue: 4
Author(s): Anastazia Kei, Evangelos N. Liberopoulos and Moses S. Elisaf
Affiliation:
Keywords: Adverse events, niacin, nicotinic acid, side effects, toxicity, laropiprant, high density lipoprotein, gastrointestinal disorders, flushing, rash
Abstract: Nicotinic acid is the oldest hypolipidemic agent in use, since 1955. It possesses broad-spectrum lipidmodifying properties including reduction of total cholesterol, low density lipoprotein (LDL) cholesterol and triglycerides. In addition, nicotinic acid is the most potent available hypolipidemic agent for increasing plasma high density lipoprotein (HDL) cholesterol and decreasing lipoprotein (a) levels. Clinical trials have demonstrated that nicotinic acid can decrease cardiovascular morbidity and mortality. However, nicotinic acid is underused in the clinical setting due to its high rate of side effects, including flushing, gastrointestinal disorders, rash, hyperglycemia and hyperuricemia. The nicotinic acid-associated side effects and their management are the focus of this review.
Export Options
About this article
Cite this article as:
Kei Anastazia, N. Liberopoulos Evangelos and S. Elisaf Moses, What Restricts the Clinical Use of Nicotinic Acid?, Current Vascular Pharmacology 2011; 9 (4) . https://dx.doi.org/10.2174/157016111796197215
DOI https://dx.doi.org/10.2174/157016111796197215 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Sibutramine Effects on Central Mechanisms Regulating Energy Homeostasis
Current Neuropharmacology The Effects of CCRC on Cognition and Brain Activity in aMCI Patients: A Pilot Placebo Controlled BOLD fMRI Study
Current Alzheimer Research Editorial [Hot topic: Infective Endocarditis (Guest Editor: Ioannis Starakis)]
Cardiovascular & Hematological Disorders-Drug Targets Viral Myocarditis and Dilated Cardiomyopathy: Etiology and Pathogenesis
Current Pharmaceutical Design Perspectives on Medicinal Properties of Mangiferin
Mini-Reviews in Medicinal Chemistry Gene Delivery Strategies Targeting Stable Atheromatous Plaque
Current Pharmaceutical Design Lipases as Modulators of Atherosclerosis in Murine Models
Current Drug Targets Molecular Imaging of Vascular Inflammation
Current Pharmaceutical Design Insulin Resistance in the Early Stages of Renal Failure: Implications for Cardiovascular Risk
Current Diabetes Reviews Mevalonate Pathway and Human Cancers
Current Molecular Pharmacology Emerging Role of Antioxidants in the Protection of Uveitis Complications
Current Medicinal Chemistry Immune Response to Native Lipoproteins Induces Visceral Obesity and Aortic Wall Injury in Rats: The Role of Testosterone
Endocrine, Metabolic & Immune Disorders - Drug Targets The Fibroblast Growth Factor 23: A New Player in the Field of Cardiovascular, Bone and Renal Disease
Current Vascular Pharmacology Preface
Current Drug Targets - Infectious Disorders The Role of P2Y<sub>12</sub> Receptor and Activated Platelets During Inflammation
Current Drug Targets Preface
Current Pharmaceutical Design The Antidiabetic PPARγ Ligands: An Update on Compounds in Development
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Diabetic Heart and the Cardiovascular Surgeon
Cardiovascular & Hematological Disorders-Drug Targets Preface
Current Topics in Medicinal Chemistry Recent Patent in Controlled Porosity Osmotic Pump
Recent Patents on Drug Delivery & Formulation